secwatch.observer — SEC 8-K summary
======================================

Issuer:     BriaCell Therapeutics Corp. (BCTX)
CIK:        0001610820
Form:       8-K
Filed at:   2025-06-18T23:59:59+00:00
Accession:  0001641172-25-015516
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BriaPro Therapeutics (2/3 owned by BriaCell) reports net loss of $519,804 for 9 months, cash only $1
--------------------------------------------------------------------------------

- Net loss of $519,804 for nine months ended April 30, 2025 vs. $316,517 in prior year period.
- Accumulated deficit $960,013; cash and cash equivalents $1.
- Due to related parties (BriaCell group) $937,432, up from $424,654 at July 31, 2024.
- Warrant liability revalued to $176,409 from $149,841; change in fair value gain of $26,568.
- Going concern uncertainty: company has not commenced commercial operations and expects further losses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610820/000164117225015516/0001641172-25-015516-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610820/000164117225015516/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-015516

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer